Overview

Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)

Status:
Not yet recruiting
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, open label, phase II study.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Collaborator:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Docetaxel
Gemcitabine
Paclitaxel
Pemetrexed